Skip to content

Study · Randomized controlled trial · n = 47 · 2019

6 results

A double-blind, placebo-controlled, randomised trial to assess the effect of liraglutide on ectopic fat accumulation in South Asian type 2 diabetes patients.

van Eyk HJ, Paiman EHM, Bizino MB, de Heer P, Geelhoed-Duijvestijn PH, Kharagjitsingh AV, Smit JWA, Lamb HJ, Rensen PCN, Jazet IM

Cardiovascular diabetology9 Jul 2019Cited by 70 (Europe PMC)

PMID31288820 (opens in a new tab)PMCIDPMC6615254 (opens in a new tab)DOI10.1186/s12933-019-0890-5 (opens in a new tab)PepBankPUB-31288820
Download PDFPubMedAsk about this study
Jump to 6 results

Summary

BackgroundSouth Asians have a high risk to develop type 2 diabetes, which may be related to substantial ectopic fat deposition. Since glucagon-like peptide-1 analogues can reduce ectopic fat accumulation, the aim of the present study was to assess the effect of treatment with liraglutide for 26 weeks on ectopic fat deposition and HbA1c in South Asian patients with type 2 diabetes.MethodsIn a placebo-controlled trial, 47 South Asian patients with type 2 diabetes were randomly assigned to treatment with liraglutide (1.8 mg/day) or placebo added to standard care. At baseline and after 26 weeks of treatment we assessed abdominal subcutaneous, visceral, epicardial and paracardial adipose tissue volume using MRI. Furthermore, myocardial and hepatic triglyceride content were examined with proton magnetic resonance spectroscopy.ResultsIn the intention-to-treat analysis, liraglutide decreased body weight compared to placebo (- 3.9 ± 3.6 kg vs - 0.6 ± 2.2 kg; mean change from baseline (liraglutide vs placebo): - 3.5 kg; 95% CI [- 5.3, - 1.8]) without significant effects on the different adipose tissue compartments. HbA1c was decreased in both groups without between group differences. In the per-protocol analysis, liraglutide did decrease visceral adipose tissue volume compared to placebo (- 23 ± 27 cm2 vs - 2 ± 17 cm2; mean change from baseline (liraglutide vs placebo): - 17 cm2; 95% CI [- 32, - 3]). Furthermore, HbA1c was decreased by liraglutide compared to placebo (- 1.0 ± 0.8% (- 10.5 ± 9.1 mmol/mol)) vs (- 0.6 ± 0.8% (- 6.1 ± 8.8 mmol/mol)), with a between group difference (mean change from baseline (liraglutide vs placebo): - 0.6% (- 6.5 mmol/mol); 95% CI [- 1.1, - 0.1 (- 11.5, - 1.5)]). Interestingly, the decrease of visceral adipose tissue volume was associated with the reduction of HbA1c (β: 0.165 mmol/mol (0.015%) per 1 cm2 decrease of visceral adipose tissue volume; 95% CI [0.062, 0.267 (0.006, 0.024%)]).ConclusionsWhile the intention-to-treat analysis did not show effects of liraglutide on ectopic fat and HbA1c, per-protocol analysis showed that liraglutide decreases visceral adipose tissue volume, which was associated with improved glycaemic control in South Asians. Trial registration NCT02660047 (clinicaltrials.gov). Registered 21 January 2016.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In South Asian adults with type 2 diabetes, liraglutide decreased body weight more than placebo in the intention-to-treat analysis.

    In plain wordsIn South Asian adults with type 2 diabetes, liraglutide reduced body weight more than placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody weight change (intention-to-treat)
    Study

    n = 47

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    1.8 mg/day · 26 weeksAs given in this study (human).

    Measurements

    Body weight change
    −3.9 kg
    liraglutide
    Body weight change
    −0.6 kg
    placebo

    Source sentences

    Summary
    In the intention-to-treat analysis, liraglutide decreased body weight compared to placebo (- 3.9 ± 3.6 kg vs - 0.6 ± 2.2 kg; mean change from baseline (liraglutide vs placebo): - 3.5 kg; 95% CI [- 5.3, - 1.8])
    1 context sentence
    Summary · context
    In a placebo-controlled trial, 47 South Asian patients with type 2 diabetes were randomly assigned to treatment with liraglutide (1.8 mg/day) or placebo added to standard care.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In South Asian adults with type 2 diabetes, liraglutide had no significant effect on the different adipose tissue compartments in the intention-to-treat analysis.

    In plain wordsIn South Asian adults with type 2 diabetes, liraglutide did not significantly change fat volume in the measured body areas in the main analysis.

    Peptide
    Liraglutide
    Outcome
    No significant changeAdipose tissue compartment volumes (intention-to-treat)
    Study

    n = 47

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    1.8 mg/day · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    without significant effects on the different adipose tissue compartments.
    1 context sentence
    Summary · context
    In a placebo-controlled trial, 47 South Asian patients with type 2 diabetes were randomly assigned to treatment with liraglutide (1.8 mg/day) or placebo added to standard care.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In South Asian adults with type 2 diabetes, HbA1c decreased in both groups with no between-group difference in the intention-to-treat analysis.

    In plain wordsIn South Asian adults with type 2 diabetes, HbA1c fell in both groups, with no difference between liraglutide and placebo in the main analysis.

    Peptide
    Liraglutide
    Outcome
    No significant changeHbA1c (intention-to-treat)
    Study

    n = 47

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.8 mg/day · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    HbA1c was decreased in both groups without between group differences.
    1 context sentence
    Summary · context
    In a placebo-controlled trial, 47 South Asian patients with type 2 diabetes were randomly assigned to treatment with liraglutide (1.8 mg/day) or placebo added to standard care.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In South Asian adults with type 2 diabetes, liraglutide decreased visceral adipose tissue volume compared with placebo in the per-protocol analysis.

    In plain wordsIn South Asian adults with type 2 diabetes, liraglutide reduced belly (visceral) fat more than placebo in the per-protocol analysis.

    Peptide
    Liraglutide
    Outcome
    DecreaseVisceral adipose tissue volume (per-protocol)
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    1.8 mg/day · 26 weeksAs given in this study (human).

    Measurements

    Visceral adipose tissue change
    −23 cm2
    liraglutide
    Visceral adipose tissue change
    −2 cm2
    placebo

    Source sentences

    Summary
    In the per-protocol analysis, liraglutide did decrease visceral adipose tissue volume compared to placebo (- 23 ± 27 cm2 vs - 2 ± 17 cm2; mean change from baseline (liraglutide vs placebo): - 17 cm2; 95% CI [- 32, - 3])
    1 context sentence
    Summary · context
    In a placebo-controlled trial, 47 South Asian patients with type 2 diabetes were randomly assigned to treatment with liraglutide (1.8 mg/day) or placebo added to standard care.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In South Asian adults with type 2 diabetes, liraglutide decreased HbA1c more than placebo in the per-protocol analysis.

    In plain wordsIn South Asian adults with type 2 diabetes, liraglutide lowered HbA1c more than placebo in the per-protocol analysis.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c (per-protocol)
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.8 mg/day · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    Furthermore, HbA1c was decreased by liraglutide compared to placebo (- 1.0 ± 0.8% (- 10.5 ± 9.1 mmol/mol)) vs (- 0.6 ± 0.8% (- 6.1 ± 8.8 mmol/mol)), with a between group difference (mean change from baseline (liraglutide vs placebo): - 0.6% (- 6.5 mmol/mol); 95% CI [- 1.1, - 0.1 (- 11.5, - 1.5)])
    1 context sentence
    Summary · context
    In a placebo-controlled trial, 47 South Asian patients with type 2 diabetes were randomly assigned to treatment with liraglutide (1.8 mg/day) or placebo added to standard care.
  6. 06HumanRandomized controlled trialOther

    In South Asian adults with type 2 diabetes, the decrease of visceral adipose tissue volume was associated with the reduction of HbA1c.

    In plain wordsIn South Asian adults with type 2 diabetes, a larger drop in belly fat was linked to a larger drop in HbA1c.

    Peptide
    Liraglutide
    Outcome
    Not applicableAssociation of visceral fat decrease with HbA1c reduction
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.8 mg/day · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    Interestingly, the decrease of visceral adipose tissue volume was associated with the reduction of HbA1c (β: 0.165 mmol/mol (0.015%) per 1 cm2 decrease of visceral adipose tissue volume; 95% CI [0.062, 0.267 (0.006, 0.024%)]).
    1 context sentence
    Summary · context
    In a placebo-controlled trial, 47 South Asian patients with type 2 diabetes were randomly assigned to treatment with liraglutide (1.8 mg/day) or placebo added to standard care.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4NCT02660047

Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients of South Asian Descent

Leiden University Medical Centern = 51Aug 2015 to 9 Mar 2018

Diabetes Mellitus Type 2 · Metabolic Syndrome · Cardiovascular Disease · Diastolic Dysfunction · Fatty Liver

Trial pageClinicalTrials.govUpdated 21 Mar 2018

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.